Ovr110 antibody compositions and methods of use

Details Ovr110 antibody compositions and methods of use Ovr110 antibody compositions and methods of use

2011-06-21

2011-06-21

Reddig, Peter J (Department: 1642)

Drug, bio-affecting and body treating compositions

Conjugate or complex of monoclonal or polyclonal antibody,...

C424S181100, C424S183100, C530S391100, C530S391700

Reexamination Certificate

active

07964195

ABSTRACT:
The invention provides isolated anti-head and neck, ovarian, pancreatic, lung, endometrial or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The invention also encompasses compositions comprising an anti-Ovr110 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr110 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr110 antibodies. The invention encompasses a method of producing the anti-Ovr110 antibodies. Other aspects of the invention are a method of killing an Ovr110-expressing cancer cell by contacting the cancer cell with an anti-Ovr110 antibody and a method of alleviating or treating an Ovr110-expressing cancer in a mammal by administering a therapeutically effective amount of the anti-Ovr110 antibody to the mammal.

REFERENCES:
patent: 7619068 (2009-11-01), Pilkington et al.
patent: 2003/0181692 (2003-09-01), Ni et al.
patent: 2004/0180002 (2004-09-01), Young et al.
patent: 2004/0197328 (2004-10-01), Young et al.
patent: 2009/0136490 (2009-05-01), Pilkington et al.
patent: WO 00/12758 (2000-09-01), None
patent: WO 04/000221 (2003-12-01), None
patent: WO 2004/101756 (2004-11-01), None
patent: WO 2004/101756 (2004-11-01), None
patent: WO 2004/113500 (2004-12-01), None
patent: WO 2006/053110 (2006-05-01), None
Gura (Science, 1997, 278:1041-1042).
Bradley, P. (Cur. Opin. Otolaryngol. Head Neck Surg. 2004 12: 127-132).
Kaiser (Science, 2006, 313: 1370).
Roitt et al. (Immunology, Third Edition (Mosby, London England) p. 1.7, 1993).
Zhang et al., “B7-H1-targeted immunotherapy for head and neck cancer”, Expert Opin Biol Ther 2004 4(10):1577-1583.
Choi et al. “Genomic Organization and Expression Analysis of B7-H4, an Immune Inhibitory Molecule of the B7 Family” The Journal of Immunology 2003 171:4650-4654.
Loke, P. and Allison, J. P. “Emerging Mechanisms of Immune Regulation: the Extended B7 Family and Regulatory T Cells” Arthritis Research and Therapy 2004 6(5):208-214.
Prasad et al. “B7S1, a Novel B7 Family Member that Negatively Regulates T Cell Activation” Immunity 2003 18:863-873.
Sica et al. “B7-H4, a Molecule of the B7 Family, Negatively Regulates T Cell Immunity” Immunity 2003 18:849-861.
Zang et al. “B7x: A Widely Expressed B7 Family Member that Inhibits T Cell Activation” PNAS 2003 100(18):10388-10392.
Supplementary European Search Report from 10158491.0-1223, Aug. 16, 2010.
Carreno, B.M. and Collins, M. “BTLA: a New Inhibitory Receptor with a B7-like Ligand” Trends in Immunology 2003 vol. 24(10): 524-527.
Collins et al. “The B7 Family of Immune-regulatory Ligands” Genome Biology 2005 vol. 6(6): 223.1-223.7.
Greenwald et al. “The B7 Family Revisited” Annual Review of Immunology 2005 vol. 25: 515-548.
Ichikawa, M. and Chen, L. “Role of B7-H1 and B7-H4 Molecules in Down-regulating Effector Phase of T-cell Immunity: Novel Cancer Escaping Mechanisms” Frontiers in Bioscience 2005 vol. 10: 2856-2860.
Ou et al. “Suppression of Human T-cell Responses to β-cells by Activation of B7-H4 Pathway” Cell Transplantation 2006 vol. 15: 399-410.
Salceda et al. “The Immunomodulatory Protein B7-H4 is Overexpressed in Breast and Ovarian Cancers and Promotes Epithelial Cell Transformation” Experimental Cell Research 2005 vol. 306: 128-141.
Tringler et al. “B7-H4 is Highly Expressed in Ductal and Lobular Breast Cancer” Clinical Cancer Research 2005 vol. 11: 1842-1848.
Tringler et al. “B7-H4 Overexpression in Ovarian Tumors” Gynecologic Oncology 2006 vol. 100: 44-52.
Wang, S. and Chen, L. “Co-signaling Molecules of the B7-CD28 Family in Positive and Negative Regulation of T Lymphocyte Responses” Microbes and Infection 2004 vol. 6: 759-766.
Yagi et al. “Regulatory Roles of IL-2 and IL-4 in H4/Inducible Costimulator Expression on Activated CD4+T Cells During Th Cell Development” The Journal of Immunology 2003 vol. 171: 783-794.

Affiliated with

Also associated with

Rating

Ovr110 antibody compositions and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ovr110 antibody compositions and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ovr110 antibody compositions and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2659001